Synthesis and insilico investigations of amino acid derived ketomethylene derivatives of S-linked heterocycles

In the vast landscape of modern medicine, the search for new ways to fight infection often begins with the construction of tiny, specialized molecular tools. Scientists frequently turn to ring-shaped structures made of carbon and other atoms, known as heterocycles, because these shapes are naturally adept at interacting with the biological machinery of bacteria and fungi. Think of these rings as custom-made keys, designed to fit into specific locks on a pathogen's surface to disable it. To make these keys even more effective, researchers often attach them to amino acids, the fundamental building blocks of life that our bodies use to build proteins. By combining these ring structures with amino acids, chemists hope to create new compounds that can slip past a microbe's defenses and stop it from multiplying. The challenge lies in finding the right combination of shapes and chemical attachments that will bind tightly to the enemy without harming the host, a process that requires both precise chemical synthesis and careful computer modeling to predict how well the new molecules will work.

A team of researchers at REVA University recently took on this challenge by creating a new family of compounds that link these ring-shaped structures to amino acids through a sulfur bridge. Their goal was to synthesize a series of molecules where a sulfur atom connects a heterocyclic ring to a ketone group derived from an amino acid. To do this, they first prepared amino acids that had been chemically modified to include a reactive bromine atom, turning them into bromoketones. They then mixed these bromoketones with various sulfur-containing ring compounds, including 1,3,4-oxadiazoles, triazoles, thiazoles, and imidazoles. The team utilized a technique called microwave-assisted synthesis, which uses microwave radiation to heat the reaction mixture rapidly and uniformly. This method allowed them to complete the chemical reactions in just a few minutes, a significant improvement over traditional heating methods that can take hours and often produce unwanted byproducts. The result was a collection of new molecules, each featuring a unique combination of a ring structure and an amino acid, ready for testing.

Once the new compounds were created and confirmed using standard chemical analysis tools like nuclear magnetic resonance and mass spectrometry, the researchers turned to computer simulations to see how well these molecules might interact with disease-causing organisms. They focused on two specific targets: a protein from Escherichia coli bacteria known as Topoisomerase IV, which is essential for bacterial DNA replication, and an enzyme from the fungus Aspergillus niger called EstA. Using molecular docking software, they simulated the physical fit between their new compounds and these protein targets, measuring the strength of the attraction in units called kilocalories per mole. The simulations revealed that the new molecules were capable of binding to these targets with significant strength. One compound, labeled 8c, showed the strongest connection to the bacterial protein, with a binding affinity of -10.6 kcal/mol. Another compound, 8b, demonstrated the most powerful interaction with the fungal enzyme, achieving a binding affinity of -10.2 kcal/mol. These values were comparable to, and in some cases stronger than, the binding strengths of existing reference drugs like streptomycin and fluconazole.

Beyond just how well the molecules stuck to their targets, the researchers also examined the overall chemical properties of their new compounds to see if they might be suitable for use as medicines. They analyzed factors such as molecular weight, solubility, and the ability to pass through biological membranes. The simulations suggested that many of the new compounds possessed a balanced profile, with properties that would allow them to be absorbed by the human body and reach their intended targets. Specifically, several of the compounds were predicted to have high gastrointestinal absorption, meaning they could be taken orally and still reach the bloodstream effectively. The team also noted that most of the new molecules did not appear likely to cross the blood-brain barrier, which could be a safety advantage by limiting their effects to the rest of the body. While these findings are based entirely on computer models and do not yet represent a proven cure, they provide a strong indication that these specific combinations of amino acids and heterocyclic rings are worth pursuing further. The study concludes that these synthesized molecules, particularly 8c and 8b, represent promising candidates for future development as potential antibacterial and antifungal agents, offering a new direction in the ongoing effort to design effective treatments for infectious diseases.